Angioflyuks

• Structure
• Release form
• Pharmacological action
• Pharmacodynamics and pharmacokinetics
• Indications to use
• Contraindications
• Side effects
• Angioflyuks, application instruction (Way and dosage)
• Overdose
• Interaction
• Terms of sale
• Storage conditions
• Period of validity
• Analogs
• Responses

Structure

In 1 capsule of a sulodeksid 250 LE.

In 1 ml of solution of a sulodeksid 300 LE, in 2 ml — 600 LE.

Release form

Solution in ampoules for intramuscular and intravenous administration of 600 LIE/2 ml.

Capsules 250 LE.

Pharmacological action

Antikoagulyatnoye.

Pharmacodynamics and pharmacokinetics

Pharmacodynamics

Anticoagulating drug, has antitrombotichesky, fibrinolitic and angioprotektorny effect. Sulodeksid represents extract mucous a small intestine of animals as a part of which geparinopodobny fraction and dermatan-sulfate. Suppresses blood-coagulation factors of Xa and Pa, reduces concentration of fibrinogen in blood. Increases concentration of plasminogen. Angioprotektorny action is connected with recovery of integrity of cells of an endothelium.

Drug, reducing concentration of triglycerides and reducing viscosity of blood, normalizes rheological properties. In high doses anticoagulating action is shown if the drug is administered intravenously.

Pharmacokinetics

At intravenous administration it is quickly distributed on fabrics and bodies. About 90% of active ingredient are absorbed in an endothelium. Cmax at intravenous administration is reached in 5-15 minutes. Difference from heparins consists that active ingredient is not exposed to a desulfatirovaniye therefore its antitrombotichesky activity does not decrease and is not so quickly brought out of an organism. In a liver it is metabolized, removed by kidneys — within a day about 50%.

Indications to use

• the increased risk of a thrombogenesis;
• ischemia of the lower extremities;
• mikroangiopatiya (retinopathy, nephropathy);
• diabetic makroangiopatiya.

Contraindications

• hypersensitivity;
• tendency to bleedings;
• hemorrhagic diathesis;
• pregnancy;
• hypocoagulation.

Side effects

• stomach aches;
• skin rash;
• nausea, vomiting;
• hematoma in an injection site;
• pain, burning.

Angioflyuks, application instruction (Way and dosage)

Duration of treatment and dose depend on results of inspection. Treatment begin with intramuscular or intravenous administration 600 PIECES, lasting 2 weeks. Then accept in a capsule of Angioflyuks 250 PIECES 2 times a day, within 30-40 days. Treatment is repeated by 2 times a year. At treatment control blood coagulation indicators.

Overdose

Overdose is shown by bleeding. Treatment consists in drug withdrawal and carrying out symptomatic therapy.

Interaction

To avoid simultaneous use of indirect and direct anticoagulants, and also antiagregant as anticoagulating action amplifies.

Terms of sale

It is released according to the recipe.

Storage conditions

Temperature is up to 30 °C.

Period of validity

3 years.

Angioflyuks's analogs

Gemapaksan, Heparin Sandoz, Fraksiparin, Tsibor, Wessel Due F.

What to choose Angioflyuks or Wessel? Drugs have one active ingredient, the same form of release, a dosage. The producer of the last — CSC (Italy). Drugs are completely interchanged. At the same time Angioflyuks is slightly cheaper: cost is 50 capsules of Wessel Due of F 2508-2650 rub, and Angioflyuksa of 2230-2328 rub.

About Angioflyuks

Most often responses and discussions of reception of this drug at pregnancy meet. One of physiological features of a female organism during this period — increase of coagulability of blood. High levels of estrogen will provoke thrombosis therefore continuous research of level a d-dimeasure is necessary as fibrinoobrazovaniye marker. In case of positive tests for markers of a fibrinoobrazovaniye antitrombotichesky therapy is immediately appointed.

Especially watch a condition of a hemostasis and give value to this indicator after EKO as d-dimeasures after transfer of embryos can sharply increase and influence implantation and a vynashivayemost of pregnancy. According to patients, research of a condition of a hemostasis already at a stage of planning of EKO is obligatory and if this indicator is higher than norm for planning, then Angioflyuks was appointed everything.

• "… Me the doctor appointed tablets of Angioflyuks in a month by preparation for EKO".
• "… I drink two capsules a day, registered before eko".
• "… I on Angioflyuksa had a successful protocol, accepted to EKO and after".
• "… I consider drug efficient. A saw in the protocol after delivery a d-dimeasure".
• "… Found the Leydenovsky mutation, and the hematologist at once Angioflyuks appointed, it in addition to heparins!".
• "... I have a Leydenovsky mutation — from here all problems with conception, abortions and not incubation of pregnancy. Appointed this medicine".
• "… Peele all pregnancy, was appointed at first on 2 capsules a day and when added heparins — 1 capsule. Pobochek was not".
• "… I before the protocol drank it within a month, in the protocol gave injections and till 25th week".
• "… I have a blood clot after the delivery. Pricked two months fraksiparin, now I drink Angioflyuks".